In this study, cytotoxic effects of AZD5363, a Pan-AKT inhibitor, and Compound E, a gamma-secretase inhibitor, as a pre-clinical model for T-ALL therapy were evaluated. Here, AKT1 is linked to acute lymphoblastic leukemia.